Press Release Archive
Press Releases
November 2020
11.16.2020 Finance Investments Pfizer Completes Transaction to Combine Its Upjohn Business with Mylan 11.12.2020 Medicines Analysis from Phase 3 ATTR-ACT and Its Long-Term Extension Study Demonstrates VYNDAQEL® 80 mg/VYNDAMAX® 61 mg Significantly Improved Survival in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Compared to VYNDAQEL 20 mg 11.11.2020 Finance Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference 11.11.2020 Research Pfizer Announces Positive Results from Fifth Phase 3 Trial of Abrocitinib, Evaluating Safety and Efficacy Across Different Dosing Regimens 11.11.2020 Covid-19 Vaccines Pfizer and BioNTech Reach an Agreement to Supply the EU With 200 Million Doses of Their BNT162b2 mRNA-Based Vaccine Candidate Against SARS-CoV-2 11.10.2020 Medicines Pfizer Statement on Geodon (ziprasidone) Trial Closure in the United States 11.09.2020 Partnerships Homology Medicines Announces $60 Million Equity Investment from Pfizer Inc. 11.09.2020 Research Vaccines Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study 11.06.2020 Medicines Research Pfizer Announces Positive Phase 3 Study Results for XELJANZ ® (tofacitinib) in Ankylosing Spondylitis (AS) 11.05.2020 Finance Pfizer Announces Details for When-Issued and Ex-Distribution Trading of Viatris and Pfizer Common Stock
October 2020
Media Resources & Contact Information
Anyone may view our press releases, press statements, and press kits.
However, to ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.